Sumatriptan pills 100mg, 2pcs

Composition

Film-coated tablets 1 tab. sumatriptan 100 mg

Pharmacological action

Agonist of serotonin 5-HT1 receptors.

Drug with anti-migraine activity

Indications

-migraine attack with or without aura.

Contraindications

— hemiplegic, basilar or oftalmologicheskiy forms of migraine;

— ischemic heart disease or the presence of symptoms suggesting her existence;

myocardial infarction in the anamnesis;

— pharmacologically uncontrolled arterial hypertension;

— occlusive peripheral vascular disease;

stroke or transient cerebrovascular accident (including in the anamnesis);

— pronounced violations of the liver and kidneys;

— concomitant use with ergotamine or its derivatives and within 24 h after their admission;

— application in patients receiving monoamine oxidase inhibitors or earlier than 2 weeks after the cancellation of these drugs;

— age under 18 and over 65 years of age (efficacy and safety not established);

— pregnancy;

breast— feeding (breast-feeding is possible not earlier than 24 hours after taking the drug;

— congenital galactosemia, malabsorption syndrome glucose/galactose, congenital deficiency of lactose;

— hypersensitivity to any component of the drug.

With caution: epilepsy (including any condition with a reduced epileptic threshold), pharmacologically controlled arterial hypertension, impaired liver or kidney function, hypersensitivity to sulfonamides (use of sumatriptan can cause allergic reactions, the severity of which varies from skin manifestations to anaphylaxis).

Side effects

The frequency of adverse reactions listed below was determined according to the following: very often-more than 1/10; often – from more than 1/100 to less than 1/10; sometimes-from more than 1/1000 to less than 1/100; rarely-from more than 1/10 000 to less than 1/1000; very rarely – from less than 1/10 000, including individual cases.

Nervous system disorders: often – dizziness, drowsiness, sensory disturbances, including parastesias and decreased sensitivity.

From the cardiovascular system: often – a transient increase in blood pressure (observed shortly after taking the drug), “hot flashes”.

From the respiratory system and organs and cells: often-dyspnoea, mild, transient irritation of the mucous membrane or burning sensation in the nasal cavity or throat, nosebleeds.

From the gastrointestinal tract: often – nausea, vomiting.

Musculoskeletal and connective tissue disorders: often-a feeling of heaviness (usually transient, can be intense and occur in any part of the body, including the chest and throat).

General and local reactions: often – pain, a feeling of cold or heat, a feeling of pressure or constriction (usually transient, can be intense and occur in any part of the body, including the chest and throat), weakness, fatigue (usually mild or moderate, transient).

Laboratory parameters:  very rarely – minor deviations in liver test parameters.

Post-marketing surveillance

From the immune system:  very rarely – hypersensitivity reactions, including skin manifestations, as well as anaphylaxis.

Nervous system disorders:  very rarely-convulsive seizures (in some cases observed in patients with a history of convulsive seizures or with concomitant conditions predisposing to seizures; in some patients, no risk factors were identified), tremor, dystonia, nystagmus, scotoma.

From the side of the visual organs:  very rarely – flickering, diplopia, decreased visual acuity, blindness (usually transient). However, visual disturbances can be caused by a migraine attack itself.

From the cardiovascular system:  very rarely – bradycardia, tachycardia, flutter, arrhythmias, transient ECG changes, coronary vasospasm, angina pectoris, myocardial infarction, hypotension, Raynaud’s syndrome.

From the gastrointestinal tract:  very rarely – ischemic colitis, dysphagia, abdominal discomfort.

Interaction

When administered concomitantly with ergotamine and ergotamine-containing drugs, prolonged vascular spasm is possible.

Interaction between sumatriptan and MAO inhibitors is possible (decrease in the intensity of sumatriptan metabolism, increase in its concentration).

With the simultaneous use of sumatriptan and drugs from the group of selective serotonin reuptake inhibitors, weakness, hyperreflexia and impaired coordination of movements may develop.

No interaction of sumatriptan with propranolol, flunirizine, pisotifen, or ethanol was observed.

How to take, course of use and dosage

Inside, the tablet should be swallowed whole, washed down with water. Start treatment as early as possible if a migraine attack occurs. The recommended dose is 50 mg, if necessary-100 mg.

If the migraine symptoms do not disappear and do not decrease after taking the first dose, then the drug is not used again to stop the same attack.

To stop subsequent attacks (if symptoms decrease or disappear, and then resume), you can take a second dose within the next 24 hours, provided that the interval between use is at least 2 hours.

The maximum daily dose is 300 mg.

Overdose

Symptoms:  when taken orally up to 400 mg, no other side effects are observed, except for those listed above.

Treatment:  gastric lavage, observation of the patient for 10 hours, symptomatic therapy.

Special instructions

Do not use to prevent a migraine attack.

Patients at risk from the cardiovascular system should not start therapy without a preliminary examination (women in the postmenopausal period, men over the age of 40, people with risk factors for CHD).

Before prescribing sumatriptan to patients with newly diagnosed or atypical migraines, other potentially dangerous neurological diseases should be excluded. After taking sumatriptan, there may be pain and a feeling of tightness in the chest. The pain may be intense and radiate to the neck. If there is reason to believe that these symptoms are a manifestation of CHD, it is necessary to conduct an appropriate examination.

Influence on the ability to drive motor vehicles and manage mechanisms

During the treatment period, care should be taken when driving vehicles and doing other activities. potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Active ingredient

Sumatriptan

Conditions of release from pharmacies

By prescription

Dosage form

Tablets